{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:40:39Z","timestamp":1769946039794,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["GM24211"],"award-info":[{"award-number":["GM24211"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["contraceptionjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.contraception.2016.07.019","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T07:17:13Z","timestamp":1469690233000},"page":"5-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Perspectives on variability in pharmacokinetics of an oral contraceptive product"],"prefix":"10.1016","volume":"95","author":[{"given":"William J.","family":"Jusko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2016.07.019_bb0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0002-9378(90)90576-S","article-title":"Pharmacokinetics of gestagens: some problems","volume":"163","author":"Fotherby","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2016.07.019_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-199528030-00003","article-title":"Levonorgestrel. Clinical pharmacokinetics","volume":"28","author":"Fotherby","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2016.07.019_bb0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0960-0760(91)90086-K","article-title":"Intrasubject variability in the pharmacokinetics of ethynyloestradiol","volume":"38","author":"Fotherby","year":"1991","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2016.07.019_bb0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.contraception.2008.02.020","article-title":"Oral contraceptives and individual variability of circulating levels of ethinyl estadiol and progestins","volume":"78","author":"Goldzeiher","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.07.019_bb0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0010-7824(01)00276-1","article-title":"The pharmacokinetics of 750 microg levonorgestrel following administration of one single dose or two doses at 12- or 24-h interval","volume":"64","author":"Tremblay","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.07.019_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0010-7824(02)00321-9","article-title":"Pharmacokinetics of levonorgestrel 0.75mg tablets","volume":"66","author":"Kook","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.07.019_bb0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0010-7824(92)90149-N","article-title":"Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3months and, after a wash-out phase, a single oral administration of the same contraceptive formulation","volume":"46","author":"Kuhnz","year":"1992","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.07.019_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/clpt.1988.7","article-title":"Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking","volume":"43","author":"Kanarkowski","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2016.07.019_bb0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","article-title":"Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug","volume":"46","author":"Zhang","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2016.07.019_bb0050","series-title":"Guidance for industry: drug interaction studies \u2014 study, design, data analysis, implications for dosing, and labeling recommendations","author":"FDA","year":"2012"},{"key":"10.1016\/j.contraception.2016.07.019_bb0055","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1185\/03007995.2011.595780","article-title":"Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers","volume":"27","author":"Butler","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.contraception.2016.07.019_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6904-12-8","article-title":"Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial","volume":"12","author":"Kothare","year":"2012","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.contraception.2016.07.019_bb0065","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.contraception.2010.01.016","article-title":"Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women","volume":"81","author":"Westhoff","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.07.019_bb0070","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1046\/j.1528-1157.2002.57701.x","article-title":"Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women","volume":"43","author":"Ragueneau-Majlessi","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.contraception.2016.07.019_bb0075","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0149-2918(00)89083-9","article-title":"The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel","volume":"23","author":"Olsson","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.contraception.2016.07.019_bb0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2125.2005.02539.x","article-title":"The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects","volume":"61","author":"Sidhu","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2016.07.019_bb0085","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcph.187","article-title":"Effect of brivaracetam (400mg\/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women","volume":"53","author":"Stockis","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2016.07.019_bb0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2125.2008.03132.x","article-title":"Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine\/zidovudine, and ethinyloestradiol\/levonorgestrel in healthy volunteers","volume":"65 Suppl. 1","author":"Abel","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2016.07.019_bb0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40261-013-0068-y","article-title":"Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers","volume":"33","author":"Macha","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.contraception.2016.07.019_bb0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40268-015-0120-x","article-title":"Effects of fostamatinib on the pharmacokinetics of oral contraceptive, warfarin, and the statins rosuvastatin and simvastatin: results from phase I clinical studies","volume":"16","author":"Martin","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.contraception.2016.07.019_bb0105","doi-asserted-by":"crossref","first-page":"248","DOI":"10.5414\/CP201647","article-title":"No clinically relevant drug\u2013drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon(R) 30)","volume":"50","author":"Young","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2016.07.019_bb0110","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/epi.12535","article-title":"Interaction between brivaracetam (100mg\/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study","volume":"55","author":"Stockis","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.contraception.2016.07.019_bb0115","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.clinthera.2005.09.002","article-title":"Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study","volume":"27","author":"Taekema-Roelvink","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.contraception.2016.07.019_bb0120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/11590240-000000000-00000","article-title":"Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study","volume":"31","author":"Friedrich","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.contraception.2016.07.019_bb0125","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2125.1994.tb04370.x","article-title":"Lansoprazole does not affect the bioavailability of oral contraceptives","volume":"38","author":"Fuchs","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2016.07.019_bb0130","doi-asserted-by":"crossref","first-page":"668","DOI":"10.5414\/CPP44668","article-title":"Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers","volume":"44","author":"Dieterle","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2016.07.019_bb0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1208\/s12248-014-9696-2","article-title":"Workshop report: Crystal City V \u2014 quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance","volume":"17","author":"Booth","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.contraception.2016.07.019_bb0140","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.contraception.2009.04.011","article-title":"Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic\u2013pituitary-ovarian activity","volume":"80","author":"Edelman","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.07.019_bb0145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00044011-200626120-00002","article-title":"Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug: as shown by once-daily divalproex-ER","volume":"26","author":"Dutta","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.contraception.2016.07.019_bb0150","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s11095-008-9787-9","article-title":"The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms","volume":"25","author":"Sahin","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.contraception.2016.07.019_bb0155","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1023\/A:1016468018478","article-title":"Evaluation of orally administered highly variable drugs and drug formulations","volume":"13","author":"Shah","year":"1996","journal-title":"Pharm Res"},{"key":"10.1016\/j.contraception.2016.07.019_bb0160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-409X(98)00028-3","article-title":"Impact of pharmacodynamic variability on drug delivery","volume":"33","author":"Levy","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.contraception.2016.07.019_bb0165","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/bja\/aei259","article-title":"Norepinephrine kinetics and dynamics in septic shock and trauma patients","volume":"95","author":"Beloeil","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.contraception.2016.07.019_bb0170","first-page":"4480","article-title":"Intra subject variability of progesterone 200mg soft capsules in indian healthy postmenopausal female subjects under fed conditions","volume":"6","author":"Rajeswara Rao","year":"2015","journal-title":"Int J Recent Sci Res"},{"key":"10.1016\/j.contraception.2016.07.019_bb0175","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jac\/dkh175","article-title":"Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis","volume":"53","author":"Conway","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.contraception.2016.07.019_bb0180","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.clinthera.2006.09.014","article-title":"Effects of food on the single-dose pharmacokinetics\/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers","volume":"28","author":"Shah","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.contraception.2016.07.019_bb0185","series-title":"Principles of anticancer drug development","first-page":"189","article-title":"Pharmacokinetic studies in early anticancer drug development","author":"Sparreboom","year":"2010"},{"key":"10.1016\/j.contraception.2016.07.019_bb0190","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","article-title":"Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability","volume":"40","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.contraception.2016.07.019_bb0195","series-title":"Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system","author":"FDA","year":"2015"},{"key":"10.1016\/j.contraception.2016.07.019_bb0200","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.clinthera.2004.11.019","article-title":"Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol\u2013norethindrone oral contraceptive in healthy women","volume":"26","author":"Griffith","year":"2004","journal-title":"Clin Ther"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782416301731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782416301731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T04:24:34Z","timestamp":1542342274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782416301731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0010782416301731"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2016.07.019","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives on variability in pharmacokinetics of an oral contraceptive product","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2016.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}